Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks

Role of natural products towards the SARS-CoV-2: A critical review

“…Remdesivir, favipiravir, lopinavir, ritonavir, and arbidol are some of the antiviral therapy options that have been found as prospective alternatives to the medicine that is currently used to treat COVID-19. These drugs work through a variety of different methods of action, including the prevention of virus replication within host cells and the inhibition of viral entry into host cells [ [68] , [69] , [70] , [71] ]. In addition, immunotherapeutic approaches have emerged as one of the most prominent therapeutic modalities in recent years.…”

“…In addition, immunotherapeutic approaches have emerged as one of the most prominent therapeutic modalities in recent years. Anakinra, sarilumab, siltuximab, and tocilizumab are a few of the immunomodulatory and anti-inflammatory medications that have been proposed as potential treatments against COVID-19 [ 69 , [72] , [73] , [74] ]. The use of convalescent plasma treatment and monoclonal antibodies has been characterized as a potential therapeutic strategy that is both effective and reliable [ 69 , 73 ].…”

“…Anakinra, sarilumab, siltuximab, and tocilizumab are a few of the immunomodulatory and anti-inflammatory medications that have been proposed as potential treatments against COVID-19 [ 69 , [72] , [73] , [74] ]. The use of convalescent plasma treatment and monoclonal antibodies has been characterized as a potential therapeutic strategy that is both effective and reliable [ 69 , 73 ]. This method seeks to strengthen patients' immune systems and prevent them from contracting viral infection [ [69] , [70] , [71] , [72] , [73] , [74] ].…”

Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article

“…Meanwhile, rapid and highly collaborative research efforts have resulted in the approval of Covid-19 vaccines, spawning a global vaccination campaign to vaccinate a large population at the earliest for limiting the spread of COVID-19 [ [16] , [17] , [18] , [19] ]. We note that neutralizing antibodies (nAbs) that target the SARS-CoV-2 S protein is a common feature of vaccines [ [20] , [21] , [22] ], monoclonal antibodies (mAbs) [ 23 , 24 ], and convalescent plasma [ [25] , [26] , [27] ] being used for prophylaxis and therapeutic purposes against COVID-19 [ 11 , 28 , 29 ]. Conversely, drugs and medicines being used for alleviating the severity of SARS-CoV-2 in COVID-19 patients, apart from Dexamethasone, showed limited efficacy against the disease.…”

Immunomodulatory effects of zinc and its impact on COVID-19 severity

“…The COVID-19 (Coronavirus Disease 2019) pandemic has claimed the lives of over 5.5 million people worldwide, along with causing severe problems to healthcare facilities and medical infrastructure [ 1 ]. Due to a lack of efficient therapeutic candidates, the world is having a difficult time battling this outbreak.…”